CDMO Lonza is adding microbial development capabilities at its Visp, Switzerland, site. The company said the investment will support a capacity increase services...

Swiss specialty chemicals producer Arxada, which was recently sold by CDMO Lonza to private equity funds Bain Capital and Cinven, has made its first strategic move since...

Swiss CDMO Lonza is making major strides to expand its position in exosome manufacturing. This week it announced two new moves. In the first, it will acquire and operate...

The former Lonza division LSI, a specialty chemicals company active in Microbial Control Solutions (MCS) and Specialty Products Solutions (SPS), will operate under the...

Swiss CDMO Lonza and Danish clinical-stage pharma Allarity Therapeutics have agreed to develop and manufacture anti-cancer therapy dovitinib. The companies are aiming to...

Successfully managing the drug substance manufacturing of Antibody-Drug Conjugates (ADCs) requires a sophisticated understanding of the technological development process...

Swiss CDMO Lonza plans to invest an undisclosed sum to establish drug product manufacturing capabilities at its site in Guangzhou, China. The investment in the central...

Lonza has completed the carve-out of its Specialty Ingredients business as LSI and appointed a management team led by CEO Mark Doyle, a former DuPont and DowDuPont chief...